Mesoblast wins FDA approval for new potency assay for Ryoncil commercial lots

The FDA approved Mesoblast's use of a new potency assay, a T-cell proliferation inhibition bioassay, for release and stability monitoring of all new commercial lots of its mesenchymal stromal cell product Ryoncil.

Detected & updated continuously · Source: Nebula